PhytoHealth Business Summary

PhytoHealth Corp. (4108.TW) is a premier Taiwanese biotechnology firm specializing in the research, development, and commercialization of botanical new drugs. The company generates revenue primarily through the sale of its flagship prescription product, PG2 (Phyto-Genyl) Lyo. Injection—the first botanical drug approved by the Taiwan Food and Drug Administration (TFDA) for Cancer-Related Fatigue—and Oraphine soft capsules for pain management. Its business segments are divided into pharmaceutical manufacturing, clinical R&D for botanical extracts targeting ischemic stroke and osteoporosis, and a portfolio of high-end dietary supplements such as AmazPower and Qi+ Liquid Herbal Energy. PhytoHealth occupies a specialized niche as a botanical drug pioneer within a competitive landscape that includes Oneness Biotech (4743.TW), Medigen Biotechnology (3176.TW), PharmaEngine (4162.TW), and Microbio (4128.TW). While competitors often focus on synthetic small molecules or biologics, PhytoHealth maintains a dominant position in the standardized botanical extract market by leveraging its proprietary extraction technology to bridge traditional medicine with modern clinical standards. The company is a core member of the Maywufa Healthcare Group, founded by Director Lee Chen-chai (Lee Cheng-chia), a pharmacist and former National Policy Consultant who successfully transitioned the group from consumer healthcare into high-barrier drug development. Current leadership is spearheaded by Chairperson Lee Yi-li (Yili Lee), who holds an MBA from Rutgers and a background in corporate banking from Citibank and Standard Chartered, overseeing strategic growth and international licensing. She is supported by Vice Chairman and General Manager Lee I-lin (Angel Lee), a Carnegie Mellon MBA with a pedigree in pharmaceutical marketing from Janssen (Johnson & Johnson). The board is closely integrated with the Maywufa Group, ensuring stable capital backing and cross-industry synergy. Notable institutional alignment includes partnerships with the Development Center for Biotechnology (DCB) and major medical centers like Tri-Service General Hospital, positioning the leadership team at the forefront of Taiwan’s botanical innovation ecosystem.